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observed that KB1P tumors were initially hypersensitive to 
fractionated local delivery of radiotherapy, but could not be 
eradicated: tumors relapsed and eventually acquired stable 
resistance. To investigate whether HR was restored in the 
resistant tumors, we studied 53BP1 and RAD51 irradiation-
induced foci formation. Surprisingly, while restoration of HR 
was prominently found in tumors that acquired resistance to 
PARP or topoisomerase I inhibition, we did not find it in 
radiotherapy resistant tumors. To investigate this discrepancy 
more closely, 53BP1 and related repair factors were knocked 
out in cell lines derived from the KB1P model using the 
CRISPR/Cas9 technology. Consistent with our in vivo data, 
clonogenic assays showed that the knock-out of 53BP1 
conferred strong resistance to PARP1 inhibition. Intriguingly, 
the lack of 53BP1 sensitized BRCA1-deficient cells to 
radiotherapy. An in vitro competition assay confirmed the 
selection to maintain a functional 53BP1 allele during 
radiotherapy treatment. Based on the KB1P model, we 
therefore hypothesize that resistance mechanisms that 
frequently occur in response to PARP1 inhibition sensitize 
cells to radiotherapy. These results, and their significance to 
human cells, are currently further validated in additional in 
vivo models including patient-derived tumors. 
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Introduction: Stereotactic (ablative) body radiotherapy 
(SBRT/SABR) has been successfully used in the treatment of 
metastatic lesions and could be considered as a “curative 
option” for some oligometastatic patients. Multiple studies 
have described significant local control in brain, lung and 
liver metastases of various primary cancers. Results suggest 
SBRT/SABR could be an effective treatment extending 
patients' life span.  
Study: For example in our retrospective study involved 90 
patients, designed to test potential effectiveness of SBRT in 
the treatment of oligometastases irrespective of primary 
Between July 2007 and June 2010, 90 patients were treated 
with robotic SBRT/SABR for hepatic or pulmonary metastatic 
lesions. A total of 113 liver and 26 lung metastatic lesions in 
52 men (58%) and 38 women (42%) were treated. Median 
follow-up was 17 months. Median age at treatment was 65 
years (range, 23-84 years). Primary cancers were 63 GI, three 
lung, eight breast, four melanoma, three neuro-endocrine 
tumors, and three sarcomas. Median diameter of the lesions 
was 28 mm (range, 7-110 mm) for liver and 12.5 mm (range, 
5-63.5 mm) for lung. Local control rates at 1 and 2 years 
were 84.5% and 66.1%, respectively. Two-year overall survival 
rate was 70% (95% CI: 55-81%). The 1 and 2-year disease-free 
survival rates were 27% (95% CI: 18-37%) and 10% (95% CI: 4-
20%), respectively. Median duration of disease-free survival 
was 6.7 months (95% CI: 5.1-9.5 months). Observed toxicities 
included grade 1-3 acute toxicities. One grade 3 and no grade 
4 toxicity were reported. High-dose SBRT/SABR for 
metastatic lesions is both feasible and effective with high 
local control rates.  
Discussion: In the last 4 years, some reports have described 
the so call abscopal effect described as “an action at a 
distance from the irradiated volume but within the same 
organism.” Abscopal effect may be more pronounced in 
response to ablative (> 10 Gy) rather than conventional 
dosage or fractionation schedules and has been reported 
mostly in renal cell carcinoma and in melanoma. The effect is 
attributed to activation of the systemic immune response by 
increase antigen presentation (neo antigens released after 
rapid cell necrosis) and enhanced immune response. These 
concepts may be of clinical value, improving outcomes by 
inducing systemic abscopal effects and potentially combined 
SBRT/SABR with immunotherapy or lymphocytes activating 
agents. Furthermore, these results have raised the question 
whether classic radiobiological modeling, and the linear-
quadratic (LQ) model, are appropriate for large doses per 
fraction with the possibility of such an additional biological 
effects resulting from endothelial cell damage, enhanced 
tumor immunity, or both. These concepts will be discussed at 
the time of presentation.  
Conclusion: SBRT/SABR treatment is well tolerated with low 
toxicity rates. It could represent an interesting treatment 
option for oligometastatic patients not amenable to surgery, 
even when patients had been pre-treated with 
chemotherapy. The biological models behind the observed 
clinical efficacy are currently scrutinized. New combined 
treatment may be driven from such promising results. 
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Optimal treatment of head and heck squamous cell 
carcinoma (HNSCC) patients requires well organized 
interdisciplinary coordination. Standard treatment of locally 
advanced HNSCC is chemoradiation or surgery followed by 
chemoradiation. Cisplatin containing chemotherapy remains 
standard of care in combination with concurrent 
radiotherapy. Neither neoadjuvant chemotherapy, nor 
treatments with targeted drugs have changed this standard, 
although some data suggest that cetuximab can be used as 
substitute for cisplatin especially in HPV/p16 positive 
disease. Combinations of cetuximab or other EGFR1 
antagonists with chemoradiation did not improve patient’s 
outcome, but added toxicity. Overall, attempts to improve 
clinical outcome in locally advanced HNSCC with targeted 
drugs and new cytostatic drugs have not been successful. The 
situation is different in locoregionally recurrent HNSCC not 
amenable for local treatment and in metastatic disease. In 
these patients, the addition of cetuximab to cisplatin and 
5FU resulted in a significant survival benefit and 
consequently is considered as standard of care.  
HPV/p16 positive HNSCC represents a distinct entity, which is 
more sensitive to radiotherapy and cytotoxic drugs. Several 
strategies testing deescalated treatments are being tested in 
randomized trials. However, deescalated is not yet 
recommended outside clinical trials.  
Neoadjuvant chemotherapy followed by radiotherapy +/- 
chemotherapy or cetuximab, and primary chemoradiation 
have been shown to allow for organ preservation especially in 
laryngeal cancer in the majority of patients without 
compromising overall survival. However, adequate selection 
of patients is critical to obtain organ preservation with good 
functional outcome.  
Recent technological developments in surgery and 
radiotherapy like transoral robotic surgery and radiotherapy 
using intensity modulated radiotherapy (IMRT), volumetric 
modulated arc therapy (VMAT), image guided radiotherapy 
(IGRT), and stereotactic body radiation therapy (SBRT) have 
been evaluated in cohort studies and a few randomized 
trials. These technologies are suitable for decreasing early 
and late toxicity and improvement of functional outcome, 
but have not been shown to improve locoregional control, 
disease free survival, and overall survival.  
The available data on the topics addressed above will be 
shown and discussed. 
 
 
 
 
